大津智 ((Unregistered) (Unregistered)) - マイポータル

基本情報

所属: 大分大学医学部講師

J-GLOBAL ID: 201801002904259889
researchmap会員ID: B000309785

研究分野

ライフサイエンス / 腫瘍診断、治療学 /

論文

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301).

Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa, Shiho Arima …

Scientific reports 15(1) 3427-3427 2025年1月27日査読有り
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).

Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, Taiga Otsuka, Yuki Sonoda, Takuya Honda, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa …

Therapeutic advances in medical oncology 17 17588359251320768-17588359251320768 2025年査読有り
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.

Tomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Yuki Sonoda, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa …

Oncology 1-11 2024年10月19日査読有り
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.

Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda …

Scientific reports 14(1) 16906-16906 2024年7月23日査読有り
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.

Tomoko Kodama, Takashi Imajima, Mototsugu Shimokawa, Taiga Otsuka, Masahiro Kawahira, Junichi Nakazawa, Takeshi Hori, Taro Shibuki, Shiho Arima, Akio Ido …

Scientific reports 14(1) 12422-12422 2024年5月30日査読有り
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori …

Scientific reports 14(1) 5311-5311 2024年3月4日査読有り
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.

Toshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, Toshiki Masuishi, Yasushi Tsuji, Hirokazu Shoji, Kenro Hirata, Takao Tsuduki, Akitaka Makiyama, Naoki Izawa …

Targeted oncology 19(2) 181-190 2024年3月査読有り
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.

Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima …

Scientific reports 13(1) 19399-19399 2023年11月8日査読有り
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer.

Satoshi Otsu, Shuichi Hironaka

Cancers 15(18) 2023年9月14日査読有り筆頭著者
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.

Azusa Komori, Satoshi Otsu, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Yoshinobu Okabe …

International journal of clinical oncology 28(8) 1073-1081 2023年8月筆頭著者
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.

Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho …

Cancer medicine 12(14) 14988-14999 2023年7月査読有り
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.

Tadayoshi Hashimoto, Satoshi Otsu, Shuichi Hironaka, Atsuo Takashima, Junki Mizusawa, Tomoko Kataoka, Haruhiko Fukuda, Shunsuke Tsukamoto, Tetsuya Hamaguchi, Yukihide Kanemitsu

Future oncology (London, England) 19(23) 1593-1600 2023年7月査読有り責任著者
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Tsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, Taiga Otsuka, Yudai Shinohara, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Satoshi Otsu, Azusa Komori …

Scientific reports 13(1) 8815-8815 2023年5月31日査読有り
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.

Yasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori …

Anticancer research 43(4) 1817-1826 2023年4月査読有り
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.

Junichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, Machiko Kawahira, Shiho Arima, Akio Ido, Futa Koga, Yujiro Ueda, Azusa Komori, Satoshi Otsu …

Oncology 101(1) 22-31 2023年査読有り
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.

Kazuo Nishikawa, Shuichi Hironaka, Takashi Inagaki, Azusa Komori, Satoshi Otsu, Kenji Mitsugi, Akitaka Makiyama, Koichiro Watanabe, Shingo Tamura, Yuta Okumura …

Japanese journal of clinical oncology 52(12) 1416-1422 2022年12月5日査読有り
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.

Takahiko Ito, Atsuo Takashima, Kentaro Yamazaki, Hiroki Yukami, Hiroyuki Uetake, Masahiro Tsuda, Takeshi Suto, Toshikazu Moriwaki, Naotoshi Sugimoto, Hitoshi Ojima …

International journal of clinical oncology 27(9) 1450-1458 2022年9月査読有り
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).

Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori …

BMC cancer 22(1) 19-19 2022年1月3日査読有り
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).

Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, Kenichiro Murayama, Shunya Nakashita, Noriko Oza, Norio Ureshino, Hirokazu Takahashi, Yujiro Ueda, Junichi Nakazawa …

Journal of geriatric oncology 13(1) 82-87 2022年1月査読有り
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).

Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, Akio Ido, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Masaru Fukahori …

Pancreas 50(7) 957-964 2021年8月1日査読有り

もっとみる